Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 29th World Cardiology Conference Edinburgh, Scotland.

Day 2 :

Conference Series World Cardiology 2018 International Conference Keynote Speaker Gary L Murray photo

Gary L Murray received a Phi Beta Kappa Bachelor’s degree from Rhodes College, Memphis, TN, USA, receiving the Belk Bible Award for the most outstanding Bible student. After graduating from the Tulane University School of Medicine, New Orleans, LA, USA, his Postdoctoral training was at the University of Tennessee Center of Health Care Sciences, Memphis, TN, USA. He became Co-Director of the Cardiac Catheterization as well as Nuclear Cardiology laboratories at Baptist Hospital, Memphis, TN, USA. He then became Chief of Medicine, Nellis AFB, North Las Vegas, NV, USA. Since, he has been in private practice in Memphis, yet he has managed to publish several articles and co-created the Shad-Murray first pass RNA exercise test for coronary disease that was employed at many centers in the USA and Europe. He participated in clinical trials of the first elective coronary stent, as well as the first coronary atherectomy and laser devices. His ANS studies have been cited in the new textbook on clinical autonomic disorders by Colombo. He has spoken in several countries worldwide. He currently is Director of Research at the Heart and Vascular Institute, Germantown, TN, USA


Background: Ranolazine (RAN) reduces the late sodium current (INa) in congestive heart failure (CHF), reducing myocardial calcium overload, thereby potentially improving left ventricular (LV) function. RAN also blocks neuronal sodium channel 1.7 (Nav 1.7), potentially altering parasympathetic and sympathetic (P & S) activity.

Objective: The objective of the study is to report RAN’s effect upon LV ejection fraction (LVEF), P & S function, and major adverse cardiac events (MACE) in CHF.

Methods: New York Heart Association (NYHA) class 2-4 CHF patients were given open-label RAN, 1000 mg p.o. b.i.d. (RANCHF, 41 systolic, 13 diastolic) added to guideline-driven therapy, or no adjuvant therapy (NORANCHF, 43 systolic, 12 diastolic). Echocardiographic LVEF was measured at baseline, confirmed by a nuclear multi-gated acquisition (MUGA) study, and reassessed yearly. P & S measures (ANX 3.0, ANSAR, Inc., Philadelphia, PA) were obtained every 6 mo. (mean follow-up 22.8 months), and MACE (cardiac deaths, CHF hospitalizations, ventricular tachycardia [VT]/ventricular fibrillation [VF] therapies) were recorded.

Results: Systolic RANCHF patients’ LVEF increased from 0.30 to 0.36 (p=0.001); diastolic RANCHF patients’ LVEF increased from 0.43 to 0.52 (p=0.002). NORANCHF patients’ LVEF remained unchanged. In RANCHF patients, P & S measures demonstrated improved sympathovagal balance (SB=S/P). SB worsened in NORANCHF subjects. MACE were qualitatively reduced in RANCHF vs. NORANCHF patients: deaths 5.6% vs. 12.7%; CHF admissions 22.2% vs. 27.3%; and VT/VF events 11.1% vs. 23.6%. Of the independent predictors for MACE, SB performed slightly better than LVEF: when SB was ≤2.5 or LVEF was ≥0.32, 80% of subjects were MACE-free; when SB was >2.5, 59% of patients suffered MACE, vs. 50% of patients when LVEF was <0.32.

Conclusion: RAN improves LVEF and autonomic function in CHF patients. RAN qualitatively reduced MACE, and SB performs slightly better than LVEF for prognostication.

  • Session: Cardiac Electrophysiology | Interventional Cardiology | Vascular Heart Diseases |Cardiomyopathy & Heart Failure
Location: Meeting Hall: Gifford


Gary L. Murray

Research Heart and Vascular Institute, USA


Marco Bertini has his expertise in Clinical Pharmacology. He is a Medical Doctor with a PhD in Clinical Pharmacology and Paediatrics. He was teaching Clinical Pharmacology in Pisa University, Italy and is actually involved in R&D in a Pharmaceutical Company (Laboratori Baldacci SpA). He has published more than 100 articles on different medical topics and was invited as “Speaker” in different international congresses. He is an Editorial Board Member of different international journals and is actively involved in Translational Medicine.


Statement of the Problem: Iron deficiency (ID) either with or without anemia (IDA), is an important comorbidity in heart failure (HF) patients and is associated with a worse prognosis. ID is present in approximately 50% of patients with HF with reduced left ventricular ejection fraction (HFrEF) and is an independent predictor of reduced functional capacity and mortality. Inexpensive and readily available oral iron supplementation, also at high dosage, has been demostrated to be uneffective in improving exercise capacity over 16 weeks ( ). Oral iron replacement treatment with the new compound Feralgine™ (a new patented co-processed oral iron preparation between ferrous bisglicinate chelate and sodium alginate) has recently demostrated to be more available than the gold-standard ferrous sulphate. The purpose of this observational study was to preliminarily understand the effectiveness of Feralgine™ supplementation in improving ID, IDA and HF symptoms during a 12 weeks treatment course.

Orientation:   A preliminary  study was been conducted on 41 HF patients (29 men and 12 women aged between 73 and 87 years old) affected by chronic heart failure (CHF) (38 patients are class III NYHA and 3 patients are IV Class NYHA) plus ID or IDA: 25 patients (60%) with HFrEF <40% and 16 (40%) with HFrEF between 40% and 50%. Every patient has been supplemented for 12 weeks with 30 mg of elemental iron belonging to Feralgine™ maintaining the previous HF drug’s treatment

Findings: At the end of oral iron supplementation (12 weeks) an increase was observed in Hb and ferritin, and surprisingly, 36 of the 41 patients (88%) had reduced their NYHA class from III to II.

Conclusion & Significance: To our knowledge this is the first time that an oral iron supplementation with low elemental iron (30 mg/daily) has shown to be effective in improve HF symptomatologies in ID/IDA-HF associated patients


Gupta P received his BE (Distinction) Degree in Electronics Engineering from Sardar Vallabhbhai National Institute of Technology, Surat (India), in 1994. He did his Master’s degree in VLSI from Malaviya National Institute of Technology, Jaipur (India) in 2008. He started his professional career with the position of Lecturer (Electronics) in Department of Technical Education (DTE), Rajasthan in 1995. Presently, he is Lecturer (Selection Grade- stage-4) in DTE, Rajasthan. He has also worked as Technical Advisor for the Government of Rajasthan from December 2014 to February 2016. His field of interest is Biomedical Signal Processing, specifically abdominal ECG signal processing, intra cellular neuronal recordings and algorithms. Apart from his engineering interests, he is greatly interested in policy issues in higher and technical education. He has a professional membership of IEEE.


Assessment of fetal heart rate (FHR) and fetal heart rate variability (fHRV) reveals important information about fetal well-being, specifically in high risk pregnancies. Abdominal electrocardiogram (abdECG) recording is a non-invasive method to capture fetal electrocardiograms. In this paper, we propose a methodology to extract FHR (fetal RR time series) from the abdECG recordings using the recently introduced multivariate empirical mode decomposition (MEMD) technique. MEMD breaks a signal into a finite set of intrinsic mode functions (IMFs). First, elimination of the noisier abdECG channels, based on comparison of similar indexed IMFs that were obtained through the MEMD technique, is conducted. Thereafter, denoising of the remaining abdECG channels is performed by eliminating certain similar indexed IMFs. The unwanted mother QRS complexes are removed from these noise-free abdECG channels, and the candidate fetal R-peaks are detected through a wavelet based approach. The proposed methodology is validated using an open source real-life clinical database. The proposed technique resulted in a high value (0.983) of cross correlation between the detected and true FHR signals.

Abid Amin Khan

Bolan Medical College, Pakistan Past President Pakistan Cardiac Society

Title: Profile of risk factors in coronary artery diseases in young south Asian population

Abid Amin was born on 25th June 1956 at Murdakarez Chaman Pakistan. He pursued his Primary and secondary school education at Islamia public school, Quetta and achieved his Intermediate certification from Govt Science College, Quetta. He received his Medical education (MBBS) from Bolan medical college Quetta 1981 and did his Post graduation diploma cardiology (dip card) 1986 NICVD Karachi and Post graduate doctor in medicine (MD-CARD) 1996 NICVD Karachi. He is the Fellow American College of cardiology (FACC) 2012 and fellow of European society of cardiology (FESC) 2013. MRCP (royal college of physician Glasgow UK ) 2013. He is the Former professor of cardiology and head of dept. of cardiology Bolan medical college Quetta. He also served as Former President Pakistan cardiac society, Vice president Pakistan hypertension league and Chairman heart failure council Pakistan cardiac society. He presented numerous papers at national and international conferences (ACC,ESC,ACC middle East, PHL,PCS). Presently he sis working as consultant cardiologist and chief executive Al- Qadeer hospital, Quetta Pakistan



CVD (cardiovascular disease) is a major health problem worldwide. It is common in older age group >55 years of age. In the current era the disease involves younger age population (45years and less) particularly in south Asian countries e.g. India, Pakistan and Bangladesh as compared to developed countries. The common risk factors for CADs are smoking, naswar (sublingual tobacco use), hypertension, diabetes mellitus, family history, sedentary lifestyle, obesity, hypercholesterolemia and hyperlipidemia (high triglyceride and low HDL). Less common risk factors are psychological stress, hyperhomosystinemia, physical inactivity, excessive food consumption (carbs and fats) and reuse of deep frying oil. Metabolic syndrome, prediabetes and diabetes are pretty common in young population of Southeast Asia. The presentation includes studies from Pakistan, Bangladesh and India on younger population, who were studied by coronary angiography, and related risk factors were evaluated by clinical and biochemical methods.

Daniela Lončar

University Clinical Center Tuzla, Bosnia and Herzegovina

Title: Risk of cardiovascular disease in dialysis patients

Daniela Lončar lives in Tuzla, Bosnia and Herzegovina. She is an internist at the Clinical Center Tuzla, Clinic for Internal diseases, ICU. She deals with the noninvasive cardiology with a particular focus of interest in echocardiography. She is senior assistant on the subject of Internal medicine at the Medical school of the University of Tuzla.


Introduction: Cardiovascular diseases are the greatest cause of morbidity and mortality in patients with chronic renal insufficiency. Patients treated with dialysis have a 10-20 times higher risk of developing cardiovascular disease than the general population. Patients with chronic kidney disease, apart from the usual, traditional risk factors for cardiovascular disease (age, diabetes, cigarette smoking, hypertension, positive family history), have additional risk factors, characteristic of the uremic syndrome, which are divided into the hemodynamic (anemia, retention of Na and H2O, AV fistula) and metabolic (hypoalbuminemia, hyperhomocysteinemia, oxidative stress, microinflammation, secondary hyperparathyroidism). The risk for cardiovascular disease may differ in patients on continuous ambulatory peritoneal dialysis and hemodialysis patients; especially in patients who remain on peritoneal dialysis for more than two years and which eventually lose their residual renal function. A part of cardiovascular damage in patients treated with dialysis is caused by the application of residual renal therapy. Therefore the question, whether hemodialysis or peritoneal dialysis is more harmful to dialysis patient, is very important.

Objectives: To identify the most frequent traditional and nontraditional risk factors for cardiovascular disease in patients on chronic dialysis (hemodialysis and continuous ambulatory peritoneal dialysis). To examine whether there is a difference in the frequency of risk factors for cardiovascular disease in patients on hemodialysis and continuous ambulatory peritoneal dialysis.

Design & Methodology: We conducted the prospective study that included 50 patients who were treated with chronic dialysis (hemodialysis and continuous ambulatory peritoneal dialysis). Subjects were divided into two groups; the test group: patients who were treated with continuous ambulatory peritoneal dialysis and the control group: patients who were treated with chronic hemodialysis. All the patients were taken anamnestic data, biochemical blood analysis, serum homocysteine ​​levels and underwent complete physical examination. The obtained data were submitted to statistical analysis using Student's t test and Chi square test. The statistical hypotheses were tested at α = 0.05, i.e. the difference between the groups was considered significant if p <0.05.

Results: The test group consisted of 15 subjects who were treated with continuous ambulatory peritoneal dialysis; the control group consisted of 35 subjects who were treated with chronic hemodialysis. The average age in the test group was 47.33 ± 13.86 years, the mean duration of continuous ambulatory peritoneal dialysis was 42.6 ± 3.72 months. The average age in the control group was 54.74 ± 16.08 years; the mean duration of hemodialysis duration was 79.05± 6.49 months. In the test group there was 5 (33.3%) men and 10 (66.7%) women; in the control group there was 17 (48.57%) men and 18 (51.43%) women.
Table 1 shows the prevalence of traditional risk factors for cardiovascular diseases by groups, there was no statistically significant difference between the test and control group.

Table 1. The prevalence of traditional risk factors for cardiovascular diseases by groups


Type of dialysis



n = 15


n = 35


2 (13,33%)

10 (28,57%)


10 (66,67%)

21 (60%)


8 (53,33%)

11 (31,40%)

Diabetes mellitus

4 (26,67%)

4 (11,43%)

Among the groups, there was no statistically significant difference between the test and control group in the incidence of anemia as non-traditional risk hemodynamic factor for cardiovascular disease. An anemia was diagnosed in 12 (80%) patients of the test group and in 31 (88.6%) patients of the control group (p - 0722). Table 2 presents the nontraditional metabolic risk factors for cardiovascular diseases by groups. There was a significant difference in central tendency for homocysteine ​​(p <0.002). Homocysteine ​​values ​​were higher in the control group compared to the test group.

Table 2: The nontraditional metabolic risk factors for cardiovascular diseases by groups


                         Type of dialysis



n = 15


n = 35


9 (60.0 %)

27 (94.28%)


6 (40.0 %)

9 (25.7 %)

Microinflamation (CRP)

8 (53.33%)

16 (45.71%)

Secondary hyperparathyroidism was verified in 17 (48.57%) patients treated with hemodialysis, and in 6 (40%) patients treated with continuous ambulatory peritoneal dialysis. There was no statistically significant difference in parathyroid hormone values ​​between the groups (p 0.986).
Conclusion: In our study we did not find statistically significant differences in the prevalence of traditional and nontraditional risk factors for cardiovascular disease among patients treated with continuous ambulatory peritoneal dialysis and hemodialysis, except for the frequency of hyperhomocysteinemia, which was significantly more prevalent among patients on hemodialysis compared to patients treated with continuous ambulatory peritoneal dialysis.
The most common traditional risk factors for cardiovascular disease in patients of both groups were hypertension and hyperlipidemia.
Anemia was present in 12 (80%) patients from the test group and 31 (88.6%) patients from the control group. The most common nontraditional metabolic risk factor for the occurrence of cardiovascular disease in patients of both groups was hyperhomocysteinemia.